ScripFinance Watch has kept a close eye on venture capital financings in 2025 because of the notable drop in mega-rounds of $100m or more, and there have been none since the last private company edition,
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Nippon Shinyaku To Commercialize Capric